SARS-CoV 2
4
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 3 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
AS
Allergy TherapeuticsUK - West Sussex
1 program1
SARS-CoV-2 convalescent plasmaPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Allergy TherapeuticsSARS-CoV-2 convalescent plasma
AB ScienceMasitinib
Faes FarmaBAT + Calcifediol
Design TherapeuticsHyperimmune plasma
Clinical Trials (4)
Total enrollment: 1,742 patients across 4 trials
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
Start: Jun 2020Est. completion: Dec 20221,225 patients
Phase 2Completed
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Start: Jun 2020Est. completion: Dec 2023
Phase 2Unknown
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
Start: May 2020Est. completion: Apr 2022517 patients
Phase 2Completed
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection
Start: Apr 2020Est. completion: Dec 2020
Phase 1/2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space